A member of the advanced prostate cancer on-line group recently posted about his experience using the newly approved chemotherapy agent, Jevtana (cabazitaxel). His post included not only a report about his PSA response to the drug, but his experiences with side effects and a suggested method of controlling one of the debilitating side effect, diarrhea. [...]
The latest from Jan Manarite of PCRI about the getting early access to Abiraterone for men with advanced prostate cancer and who have failed chemotherapy: Abiraterone expanded Access Trial Site Contact Info – 2/7/11 (800) 457-6399 M-F, 9am –5pm, EST TRIAL link: http://www.clinicaltrials.gov/ct2/show/NCT01217697?term=abiraterone&recr=Open&rank=6 Basic Criteria: 1. testosterone less than 50 2. metastatic 3. no brain [...]
The House Appropriations Committee released revised subcommittee allocations yesterday for FY 2011. The new FY 2011 Labor-HHS-Education Subcommittee allocation is $157.02 billion, which is nearly $6.6 billion (4 percent) below the subcommittee’s FY10 allocation. The House is scheduled to vote on a FY11 appropriations bill during the week of February 14. Specific funding levels and [...]
Recently, I received two separate questions about both low dose ketoconazole (LDK) and high dose ketoconacole (HDK). For both of these men with castrate resistant advanced prostate cancer, their PSA scores continued to rise, despite their using keto. Even when taken properly, not all men experience a positive effect from the drug (a decline in [...]
Malecare is proud to announce that we are now partnering with the Clinical Trials Resource Center. This partnership allows us to offer you, through our web site (www.malecare.org), CenterWatch’s data base of clinical trials that are being conducted both in the United States and internationally. CenterWatch is the leading publisher of information on clinical research [...]